


Company

ID Pharma Co., Ltd.

Presenter

Jitsutaro Kawaguchi




CytoTune[®]-iPS:

- Developed based on the Sendai Vector technology
- Capable of generating iPS cells

- 1) No chromosomal damage
- 2) Rapid clearance from the iPS cells
- 3) Excellent reprogramming efficiency
- 4) Ease of Use



Total Sales >10,000kit



Commercially Available All Over The World

ID Pharma Offers Commercial Licenses of CytoTune®-iPS

